INO — INOVIO PHARMACEUTICALS, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1055726 ·
Last close
$1.63
Market Cap
$305.31M
52W High
$2.72
52W Low
$0.56
ADV30
19,908,862
Next earnings
2026-11-10
Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 298,901 — -19,524,930 -49,204,789 60,136,243 46,962,549 94,059,215
Jun 2026 0 — -18,624,522 -6,012,458 49,389,494 31,526,164 45,018,411
Mar 2026 0 — -21,949,993 -19,682,798 49,777,142 26,271,650 43,709,260
Dec 2025 0 — -17,476,601 3,764,880 74,310,035 44,273,319 50,213,759

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-74,283,716
Investing CF
$12,447,856
Financing CF
$72,230,989
CapEx
$-285,698
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.72
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,890,065,208
Inventory
—
Receivables
$450
ST Investments
$1,398,734
EBIT TTM
$-56,334,565
Pretax Income TTM
$-71,135,165
Interest Exp TTM
$0
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$298,901
EBITDA
$-76,274,936
Free Cash Flow
$-20,820,800
Enterprise Value
$226,769,296
Total Cash
$48,361,284
Total Debt
$7,281,738
Shares Out
187,306,884
Trailing EPS
$-0.59
Book Value
$-0.18
ROE
-409.9%
ROA
-74.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 65,343 -86,822,104 -84,945,901 74,310,035 50,213,759 24,096,276 -88,629,430
Dec 2024 217,756 -112,398,922 -107,254,126 113,197,206 44,693,411 68,503,795 -104,076,553
Dec 2023 832,010 -133,426,657 -135,117,352 170,951,423 53,602,294 117,349,129 -124,365,551
Dec 2022 10,262,268 -267,573,520 -279,818,065 348,533,302 126,170,546 222,362,756 -216,215,421

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-67,427,048
OpCashFlow TTM
—
Assets (Latest)
$49,389,494
Forward EPS
$-0.03

Max Pain — expiry 2026-12-18

max pain strike: $1.00 · spot: $1.69 · call oi: 14,274 · put oi: 790
Expected Move to 2026-12-18: ±$0.48 (28.11%) — implied range $1.22 – $2.17 · ATM straddle on $1.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
LRMR Larimar Therapeutics, Inc. $310.61M $2.99 —
ALT Altimmune, Inc. $297.72M $1.53 —
GALT GALECTIN THERAPEUTICS INC $293.47M $2.91 —
AVIR Atea Pharmaceuticals, Inc. $318.00M $3.96 —
EVMN Evommune, Inc. $290.28M $7.02 —

News headlines (Yahoo Finance, 1h cache)

INOVIO Submits Conditional Marketing Authorization Application to European Medicines Agency for VOCERYQ™ in Adults with Recurrent Respiratory Papillomatosis
2026-11-18 13:05 · Yahoo
Inovio Pharmaceuticals (INO) Stock Gets Fair Value Boost After VOCERYQ Approval
2026-11-18 03:12 · Yahoo
Inovio Pharmaceuticals Inc (INO) (Q3 2026) Earnings Call Highlights: FDA Approval, Commercial ...
2026-11-12 11:03 · Yahoo
Inovio Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary
2026-11-11 13:30 · Yahoo
INOVIO to Participate in Upcoming Investor Conferences
2026-11-11 13:05 · Yahoo
Inovio (INO) Q3 2026 Earnings Call Transcript
2026-11-11 04:00 · Yahoo
Inovio: Q3 Earnings Snapshot
2026-11-10 21:25 · Yahoo
INOVIO Reports Third Quarter 2026 Financial Results and Recent Business Highlights
2026-11-10 21:05 · Yahoo
Inovio stock tumbles 25% on $75M share offering
2026-11-06 16:36 · Yahoo
INOVIO Announces Pricing of Approximately $75 Million Public Offering
2026-11-06 04:18 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.